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  A b s t r a c t
    The primary culprit responsible for Alzheimer’s disease (AD) remains unknown. A      protein has 
been identified as the main component of amyloid of senile plaques, the hallmark lesion of AD, 
but it is not definitively established whether the formation of extracellular A      deposits is the 
absolute harbinger of the series of pathological events that hit the brain in the course of spo-
radic AD. The aim of this paper is to draw attention to a relatively overlooked age-related prod-
uct, lipofuscin, and advance the hypothesis that its release into the extracellular space following 
the death of neurons may substantially contribute to the formation of senile plaques. The pres-
ence of intraneuronal A     , similarities between AD and age-related macular degeneration, and 
the possible explanation of some of the unknown issues in AD suggest that this hypothesis 
should not be discarded out of hand.     Copyright © 2011 S. Karger AG, Basel
    Unresolved Issues in the Pathogenesis of Alzheimer’s Disease
    One of the major obstacles to understanding the pathogenesis of Alzheimer’s disease 
(AD) is the difficulty of relating its highly specific neuropathological hallmarks (extracellu-
lar amyloid      , A     , deposition and       protein-based intraneuronal neurofibrillary tangles) to 
the series of generally harmful events that occur in patients’ brains and may play a major role 
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in the process of neuronal degeneration (including oxidative stress, the activation of inflam-
mation, and the deregulation of a number of basic mechanisms of cell function), or to ac-
knowledged risk factors such as head injury, altered cholesterol homeostasis, a particular 
isoform of apolipoprotein E, and cerebrovascular disease.
    Although the amyloid cascade hypothesis   [1]   sequences the two basic lesions of AD, it 
does not explain what triggers the accumulation of A      protein in the brain. Furthermore, 
many other pathogenic aspects remain largely unknown. Why does A      deposition usually 
begin in late adulthood or during aging? Why does its focal aggregation lead to a myriad 
of discrete lesions (the senile plaques) rather than diffuse involvement of the neuropil? Why 
do senile plaques form almost exclusively in the grey matter and spare the white matter 
even though the A      protein precursor is highly expressed in neurites? Why are brain re-
gions such as the cerebral cortex affected much earlier and more severely than other re-
gions?
    Not even the revised version of the A      hypothesis, which considers oligomers as the 
most detrimental factor for neuronal and synaptic functions, adds anything that can help to 
answer these questions   [2]  .
    The Morphogenesis of Senile Plaques: A Role for Lipofuscin?
    We advance a hypothesis that may provide some clues relating to the first steps in the 
genesis of senile plaques.
    Our idea is that following the death of neurons during aging (due to several unrelated 
causes), lipofuscin is set free in the neuropil, where it cannot be rapidly degraded due to its 
biochemical characteristics. Therefore, the fate of this waste product may be to linger in the 
extracellular milieu, giving rise to a focal impairment in the tissue that may represent the 
starting point of the senile plaque.   In other words, just as the young Holden Caulfield in  The 
Catcher in the Rye   was puzzled as to where the ducks of Central Park go when the lake freez-
es over, we wonder what happens to the lipofuscin built up in a neuron when the cell dies.
    Why should we imagine that the brain starts to accumulate insoluble aggregated pro-
teins focally and extracellularly from a certain point in life when the process actually begins 
with the formation of lipofuscin in the cytoplasm of neurons at birth? By middle age, the 
brain is already overloaded with a large amount of this insoluble material, which consists of 
cross-bound oxidized proteins and lipid degradation products that are highly resistant to 
cellular proteolysis   [3]  .
  Unlike previous theories concerning the possible involvement of lipofuscin in the patho-
genesis of AD   [4]  , our hypothesis does not imply that intraneuronal lipofuscin is intrinsi-
cally harmful to neuronal cells, but that it may become so when it is released into the extra-
cellular space.
    Differences in the tinctorial properties and structure of lipofuscin and the amyloid of 
senile plaques would seem to argue against our proposal. However, it must be borne in mind 
that lipofuscin contains A      and its precursor   [5, 6]  , and that its relocation from the intra- to 
the extracellular compartment (together with the intervention of microglia, astrocytes and 
a robust neuroinflammatory response) could greatly modify its morphological, tinctorial 
and biochemical characteristics.     This scenario would also reverse the most commonly held 
concept that the A     peptide self polymerize over years to form senile plaques. Following our 
view, the lipofuscin released into the extracellular space may act as a source of A     oligomers 
for a prolonged period of time.294
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    Lipofuscin as a Possible Link between A     , the Innate Immune System and
Oxidative Stress
    The hydrophobic and insoluble characteristics of lipofuscin correspond closely to those 
of substances that are most effective in inducing an innate immune response   [7]  . Further-
more, it is worth noting that mitochondrial autophagocytosis is believed to be a major con-
tributor to lipofuscin formation   [8]   and that mitochondria are the remnants of ancient bac-
terial intruders that have become symbionts of eukaryotic cells   [9]  . Finally, the rate of lipo-
fuscin formation is also closely related to oxidative stress   [3]  .
    Lipofuscin may therefore provide the missing link between the factors that are known 
to be involved in the pathogenesis of AD (such as oxidative stress, mitochondrial dysfunction 
and the activation of innate immune responses)   [10]   and the senile plaques that represent its 
earliest and most specific, microscopically visible structural alterations.
    Recent evidence indicating that vascular factors play a substantial role in the genesis of 
AD   [11]   may be interpreted in this context because hypoperfusion is a potential cause of 
damage of neurons and may therefore be capable of initiating neuronal death and lipofuscin 
release. Furthermore, the general anesthesia and perioperative procedures that have been 
shown to be associated with an increased risk of AD may act in a similar way   [12]  .
    Our hypothesis is not supported by experimental evidence, but there are also no pub-
lished data that substantially argue against it. It would therefore be very interesting to estab-
lish whether there are any differences in the biochemical composition of lipofuscin between 
AD brains and brains that are relatively resistant to developing A     deposition and AD-asso-
ciated changes. Lipofuscin, which means ‘dark fat’ and is also known as ‘age pigment’ or
‘lipopigment’, is currently defined operationally rather than structurally   [3, 8]  . Its biochem-
ical composition varies in different animal species, different brain structures and different 
ages   [13]  , thus indicating that there is not just one but many types of lipofuscin with similar 
tinctorial characteristics (autofluorescence). It is also conceivable that some types of lipofus-
cin have more deleterious effects than others when released extracellularly, and have more 
propensity to induce the formation of senile plaques.
  It is not known whether the composition of lipofuscin is different in subjects with or with-
out apolipoprotein     4  alleles. It would also be significant to determine the effect of experimen-
tally inoculated lipofuscin on the brains of mice, and whether it induces A      formation.
  Of  note,  A     deposition in AD occurs not only in the neuropil but also in vessel walls, 
and this distribution is consistent with the release of debris or waste products that follow the 
perivascular spaces when they are extruded from the cellular compartment.
    Lipofuscin in Other Age-Related Degenerative Diseases
    Lipofuscin has long been considered inert, but various lines of evidence indicate that it 
plays a major role in another neuronal degenerative process that is very common in elderly 
people: age-related macular degeneration (AMD)   [14]  . Lipofuscin accumulation in the cells 
of the retinal pigmented epithelium is involved in the pathogenesis of AMD, together with 
the formation of abnormal extracellular deposits (or drusen) that accumulate along the bas-
al surface of the pigmented epithelium. It has been shown that drusen contain a number of 
molecules and, most significantly, these include A      protein   [15]  . The fact that drusen arise 
from material released by lipofuscin-rich retinal pigmented epithelial cells and contain a 
substantial number of proteins that are also components of senile plaques suggest unexpect-
ed analogies between the pathogenetic mechanisms of AMD and AD.295
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  Conclusions
    We propose that the primary culprit responsible for sporadic AD may be the release of 
neuronal lipofuscin in the extracellular compartment, an event that should not be harmless 
since the neuron carries the weight of keeping this substance segregated inside its cytoplasm 
for decades.
  The above-mentioned ‘lipofuscin hypothesis of AD’ considers A     deposition as a down-
stream phenomenon which is critical and essential but not the absolutely and invariably 
causative event in determining the onset of AD.     It could be that in sporadic AD, A      is more 
than an epiphenomenon because it is tightly linked to the release of lipofuscin in the neuro-
pil, but that the scenario differs when A      deposition is induced artificially per se, e.g. in the 
transgenic mouse model of AD where large quantities of A      do not determine significant 
neuronal degeneration   [16]  .
    Lipofuscin is a matrix that recapitulates the insults and damage a neuron receives dur-
ing the life of an individual. It is therefore likely that its composition and characteristics are 
influenced by various genetic and environmental factors that may reinforce or weaken each 
other and, in combination with factors that alter the chance in age-related neuronal death, 
may modulate the overall individual risk of developing AD.
    Our hypothesis may open up new lines of research in addition to those currently fo-
cused on A      and      , and thus contribute to more decisive advances in our understanding of 
the pathogenesis of AD, and in the identification of effective preventive or therapeutic strat-
egies. 
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